<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940690</url>
  </required_header>
  <id_info>
    <org_study_id>FME_2018_9</org_study_id>
    <nct_id>NCT03940690</nct_id>
  </id_info>
  <brief_title>Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease</brief_title>
  <acronym>COATS-VEGF</acronym>
  <official_title>Multicenter Randomized Controlled Trial on the Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coats disease is a predominantly unilateral progressive retinal vascular disease,
      characterized by retinal telangiectasias with intra- or subretinal exudate deposits, which
      can lead to retinal detachment and one-sided blindness. Several treatment modalities are
      available and the choice of one of them depends on the stage of the disease and the habits of
      each center (laser photocoagulation, cryotherapy ...). VEGF (Vascular Endothelial Growth
      Factor) was found to be significantly elevated in the aqueous humor and subretinal fluid of
      patients with Coats disease. Several studies have shown the potential efficacy of
      intra-vitreous injections of anti-VEGF. But the results on their effectiveness have been
      evaluated only on small series of patients. Most published studies have analyzed their
      efficacy combined with another treatment, mainly laser photocoagulation. The true efficacy of
      anti-VEGF therapy as initial therapy, and then combined in Coats disease remains unknown.
      Currently, several centers are initiating first-line anti-VEGF injections, although no
      rigorous evaluation of this therapeutic strategy has been conducted.

      The identification of the best treatment regimen will allow in the future the reduction of
      laser reprocessing and will ensure a better functional benefit in the affected patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2019</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with improvement of stage of disease, according to the Shields classification</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>Stages assessed by retinal multimodal imaging (retinophotography, optical coherence tomography when age allows, retinal fluorescein angiography) by two independent expert ophthalmologists</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Retinal Telangiectasis</condition>
  <condition>Coats Disease</condition>
  <arm_group>
    <arm_group_label>Anti-VEGF injections (bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 anti-VEGF injections of bevacizumab at months 0, 1, 2, 4 and 6, combined with laser at months 2, 4 and 6 (laser optional at month 9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm : laser only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 sessions of laser at months 0, 1 and 2, completed if needed with laser at months 4, 6 et and 9</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-VEGF injections of bevacizumab</intervention_name>
    <description>5 anti-VEGF injections of bevacizumab at months 0, 1, 2, 4 and 6, combined with laser at months 2, 4 and 6 (laser optional at month 9)</description>
    <arm_group_label>Anti-VEGF injections (bevacizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser</intervention_name>
    <description>3 sessions of laser at months 0, 1 and 2, completed if needed with laser at months 4, 6 et and 9</description>
    <arm_group_label>Arm : laser only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Coats disease confirmed by fundus examination and fluorescein angiography

          -  Stage 2 or 3 at the fundus (Shields classification)

          -  Naive to any eye treatment on the eye affected by Coats disease

        Exclusion Criteria:

          -  Other ocular pathology on the eye affected by Coats' disease

          -  Bilateral forms of the disease

          -  History of hypersensitivity to bevacizumab

          -  History of hypersensitivity to products of Chinese hamster ovary cells or other
             recombinant human or humanized antibodies

          -  Allergic reaction in a previous fluorescein retinal angiogram

          -  Pregnancy or breastfeeding

          -  Active or suspected periocular infection

          -  Contraindication to treatments used for general anesthesia and morphine derivatives

          -  Cardiovascular, haemorrhagic and gastrointestinal risks

          -  Premature baby who has not reached the correct age of 37 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence METGE</last_name>
    <role>Principal Investigator</role>
    <affiliation>fmetge@for.paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurence SALOMON, MD PhD</last_name>
    <phone>148036433</phone>
    <phone_ext>+33</phone_ext>
    <email>lsalomon@for.paris</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre hospitalier René Dubos (Pontoise)</name>
      <address>
        <city>Cergy-Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard PASQUIER</last_name>
      <email>bernard.pasquier@ght-novo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Necker Enfants Malades, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique BREMOND-GIGNAC</last_name>
      <email>dominique.bremond@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique A. de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence METGE</last_name>
      <email>fmetge@for.paris</email>
    </contact>
    <contact_backup>
      <last_name>Georges CAPUTO</last_name>
      <email>gcaputo@for.paris</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carl ARNDT</last_name>
      <email>carndt@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Rive Gauche</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Léopoldine LEQUEUX</last_name>
      <email>drlequeux@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinal Telangiectasis</keyword>
  <keyword>Coats Disease</keyword>
  <keyword>Anti-VEGF (Vascular Endothelial Growth Factor)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Telangiectasis</mesh_term>
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

